Akari Therapeutics presents poster on progress on PASylated-nomacopan

Akari Therapeutics announced the presentation of progress in the development of long-acting PASylated-nomacopan as a potential treatment for geographic atrophy secondary to dry age-related macular degeneration, dAMD, in a poster at the 4th Annual Dry AMD Therapeutic Development conference. “I’m pleased with the significant progress we have made in the development of long-acting PAS-nomacopan as a geographic atrophy treatment with the potential to address significant unmet needs, including a longer dose interval with fewer needle injections into the eye and reduction in the risk of choroidal neovascularization that is associated with approved complement-only inhibitors,” said Akari Chief Scientific Officer Miles Nunn. “Part of this progress is the advancement of a high yield manufacturing process that supports our program moving into clinical trials in 2024.”